Gilead CEO insists government patent for HIV prevention pill is invalid - (The Washington Post via NewsPoints Desk)

  • Gilead Sciences CEO Daniel O'Day testified before a House of Representatives committee that the government's patent for Truvada is not valid, The Washington Post reported Thursday.

  • "Our well-supported view is that the US government does not hold valid patents on the use of Truvada for pre-exposure prophylaxis, nor does it hold any patent for Truvada itself," O'Day stated.

  • The hearing was held after a report revealed that the government had elected to not file a patent infringement lawsuit against the drugmaker despite the Centers for Disease Control and Prevention receiving a patent in 2015.

  • "This treatment was developed as a result of investment made by the American taxpayers," remarked House Oversight and Reform Committee chairman Elijah Cummings, adding "the problem is that Gilead, the company that now sells the drug, charges astronomical prices."

  • O'Day noted that the company had agreed to donate enough free courses of the drug to treat about 200 000 people each year.

  • "All of us at Gilead are proud to join with the government in our collective national effort to end HIV in the [US] by 2030," O'Day said, adding "Gilead's donation to this effort is among the largest pharmaceutical donations ever in US history."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.